Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2018-05-07 · National Institutes of Health, HHS · Notices

Notices. Notice

539 words·~2 min read·/register/2018/05/07/2018-09656·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579.
A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows. Inner Curvature Charge Concentration Device For Tissue Laceration *Description of Technology:* Left ventricular outflow tract obstruction is a life-threatening complication of transcatheter mitral valve replacement caused by septal displacement of the anterior mitral leaflet (AML).
The AML is a mobile structure that physically separates inflow and outflow zones of the left ventricle. Preserving the AML during surgical mitral valve replacement can cause left ventricular outflow tract obstruction, either when the prosthesis struts protrude into the left ventricular outflow tract or when along redundant anterior leaflet prolapses into the left ventrical outflow tract. The invention relates to devices having monopolar or bipolar tissue lacerators for efficiently and safely cutting AMLs percutaneously by vaporizing target tissue with electrical energy.
Exemplary devices include a wire partially covered by electrical insulation, where the wire is kinked and where the wire is exposed through the insulation at one or more exposed regions along or near the inner curvature of the kink. The wire is configured to conduct electrical energy through the exposed region(s) and through a tissue target positioned adjacent the inner curvature to lacerate the tissue target via the electrical energy. The tissue target can be a native or prosthetic heart valve leaflet in a patient's heart.
An optional feature of the device also includes an irrigation catheter to displace blood from the electrode, concentrating current at the tissue and reducing char and coagulum formation. Potential Commercial Applications: • Prevention of iatrogenic left ventricular outflow tract obstruction following transcatheter mitral valve replacement • Bioprosthetic aortic scallop intentional laceration Development Stage: • In vivo data available *Inventors:* Robert Lederman, Jaffar Khan, Toby Rogers (all of NHLBI). *Intellectual Property:* HHS Reference No.
E-064-2018/0-US-01; U.S. Provisional Patent Application 62/633,791 filed February 22, 2018. *Licensing Contact:* Michael Shmilovich, Esq, CLP; 301-435-5019; *shmilovm@nih.gov.* *Collaborative Research Opportunity:* The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate, please contact Peg Koelble, Technology Development Specialist, Office of Technology Transfer, National Heart, Lung, and Blood Institute, Phone: 301.594.4095; *koelblep@nhlbi.nih.gov.* Dated:
April 26, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2018-09656 Filed 5-4-18; 8:45 am]
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
  • 37 CFR 404
Citation graph
cites case law
Notices
Notice
Cite37 CFR 404
Cites 2Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.